new version V2017

Description Results

     

  • Group by...

pdf
TrialStudied treatmentControl treatmentpatientsROBResultNCT

diabetes type 2

Ahren, 2004vildagliptinplacebo (add on MET)Negative
Ristic, 2005vildagliptin monotherapyplaceboNegative
Mimori, 2006vildagliptinplacebo -
Pratley, 2006vildagliptin monotherapyplaceboNegative
Schweizer, 2007vildagliptinmetforminNegativeNCT00099866
Rosenstock** (vilda vs pio), 2007vildagliptin monotherapypioglitazone - NCT00101803
Dejager [1], 2007vildagliptin monotherapyplaceboNegativeNCT00099905
Pi-Sunyer, 2007vildagliptin monotherapyplaceboSuggestingNCT00120536
Fonseca, 2007vildagliptinplacebo (add on insulin)SuggestingNCT00099931
Bosi, 2007vildagliptinplacebo (add on MET)NegativeNCT00099892
Rosenstock** (vilda + pio vs pio), 2007vildagliptinplacebo (add on TZD)NegativeNCT00101803
Garber, 2007vildagliptinplacebo (on top pioglitazone)NegativeNCT00099853
Rosenstock* (vilda vs rosi), 2007vildagliptinrosiglitazone - NCT00099918
Bolli, 2008vildagliptinpioglitazone (add on MET)NegativeNCT00237237
Scherbaum [2], 2008vildagliptinplaceboNegativeNCT00101712
Goodman, 2009vildagliptinplacebo (add on MET) Exploratory Negative
Ferrannini, 2009vildagliptinSulfonylurea (add on to MET) Exploratory SuggestingNCT00106340



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons